TIDMVAL

RNS Number : 7026N

ValiRx PLC

26 September 2019

VALIRX PLC

("ValiRx", "the Company" or "the Group")

HALF YEARLY REPORT FOR THE PERIODED 30 JUNE 2019

London, UK., 26 September 2019: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards commercialisation and partnering, today announces its Half Yearly Report for the period ended 30 June 2019 and provides an update e on significant post-period events.

HIGHLIGHTS

Operational Highlights

-- MHRA and REC approve a major update to the trial of VAL201 including the appointment of a Principal Investigator to the clinical team, with results from the first clinical trial of the compound being prepared for an independent evaluation following the completion of the current patient group.

-- The period saw further strengthening of ValiRx's IP patent portfolio. Grant allowances for VAL301 were permitted for the European Union, China and the Russian Federation, building on an earlier patent granted in 2018 for the US. VAL201 had its IP protection extended during the period, with a patent grant allowed in the US for the use of the compound in the prevention and treatment of metastatic cancer. This allowance builds on previously granted worldwide rights for the use of the compound against prostate cancer.

-- ValiRx acquired the IP assets of FIT Biotech OY (announced 2 May 2019) to complement its other drug discovery (drug enhancing) technologies and is currently in discussions with a potential JV partner over further developing certain of the Company's genetic-based diagnostic assets

Financial Highlights

-- Loss before income tax narrowed substantially by 56.9% to GBP927,342 (H1 2018: GBP2,155,788); largely as a result of a profit on the sale of fixed asset investments and no requirement to manufacture additional VAL201 drug as sufficient quantities were produced in H2 2018;

   --      Total comprehensive loss for the period of GBP750,569  (H1 2018: GBP1,914,453); 
   --      Cash and cash equivalents as at 30 June 2019 of GBP171,443 (H1 2018: GBP590,615); and 
   --      Loss per share - basic and diluted reduced by 78.4% to (0.11)p (H1 2018: (0.51)p. 

Post-Period highlights

   --     R&D Tax Credit of GBP423,000 received in September 2019 

-- The Company announced (10 September 2019) that in addition to pharmacokinetic and toxicology data, clinical trial results show VAL201 behaves as predicted in reducing prostate cancer progression - evidence that is supported from tumour imaging (MRI and CT) in subjects.

-- VAL301's clinical team signed an agreement in July 2019 with Aptus Clinical Ltd ("Aptus"), the UK based, clinical Contract Research Organisation ("CRO"), to effectuate a clinical development plan for VAL301 incorporating a Phase I/II study design concept in Endometriosis.

-- Two placings and a subscription raised GBP1.226m of gross proceeds with existing and new investors. The funds were raised for working capital needs and to progress the development of the Company's therapeutic drug portfolio.

Oliver de Giorgio-Miller, Non-Executive Chairman of ValiRx, commented:

"Throughout the reporting period, ValiRx has continued to sustain valuable momentum in terms of progressing its therapeutic assets and along their respective clinical and pre-clinical pathways. We have made important strides forward across both our therapeutic and technology portfolios, with the expectation that these will deliver added-value in the near term for our shareholders."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

***S ***

For more information, please contact:

 
 ValiRx plc                                   Tel: +44 (0) 20 3008 4416 
                                               www.valirx.com 
 Dr Satu Vainikka, Chief Executive            Tel: +44 (0) 20 3008 4416 
 Tarquin Edwards, Head of Communications.     Tel: +44 (0) 7879 458 
                                               364 
                                               tarquin.edwards@valirx.com 
 
 Cairn Financial Advisers LLP (Nominated      Tel: +44 (0) 20 7213 0880 
  Adviser) 
  Liam Murray/Jo Turner/Ludovico Lazzaretti 
 
 Novum Securities Limited (Broker)            Tel: +44 (0) 20 7399 9400 
  Colin Rowbury 
 

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

CHAIRMAN'S STATEMENT FOR THE HALF YEARED 30 JUNE 2019

Throughout the reporting period, ValiRx has continued to sustain valuable momentum in terms of progressing its therapeutic assets and along their respective clinical and pre-clinical pathways.

VAL201

We were very pleased to announce in June 2019 that based on our clinical results for VAL201, a substantial amendment to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare products Regulatory Agency ("MHRA") and the Research Ethics Committee ("REC").

Following approval of this substantial amendment, an authoritative prostate cancer specialist, Dr Mark Linch was appointed Principal Investigator to the clinical trial team at University College London Hospital ("UCLH"). Dr Linch is the Consultant Medical Oncologist specialising in the treatment of prostate and bladder cancer at UCLH and as a recognised specialist, we are pleased to benefit from his deep understanding and experience of the condition.

To date, the results generated by the trial, showed that the compound is safe and can be given to humans at a therapeutic level and beyond. The approval given to relax the restrictions previously applied to the trial, means that a more effective use of VAL201 can be achieved, with respect to concentration and timing and regarding increased flexibility in the administration of the drug. The trial is providing practical information back to the trialling of VAL201, so that the next stage of clinical development, in which ValiRx will endeavour to show how effective the compound actually is, can be entered into with confidence and support from all those involved.

Building on this progress, ValiRx was able to announce in September 2019, that in addition to pharmacokinetic and toxicology data, clinical trial results to date show that VAL201 behaves as predicted in reducing prostate cancer progression - evidence that is supported from tumour imaging (MRI and CT) in subjects. The full data set is currently being reviewed and collated and additional data surrounding the possibility of an effect on metastatic tumour lesions is being collated in the few subjects exhibiting such tumours. This phase I/II trial will be finalised from a regulatory viewpoint with the trial focused on confirming and validating the optimum treatment regime and its particular use in clinical practice. Data relating to the pharmacology, pharmacokinetics and pharmacodynamics will be published as it is collated, verified and submitted.

VAL301

In July 2019 and just after the period end, VAL301's clinical team signed an agreement with Aptus Clinical Ltd ("Aptus"), the UK based, clinical Contract Research Organisation ("CRO"), to effectuate a clinical development plan for VAL301 incorporating a Phase I/II study design concept in endometriosis. With VAL301 being derived from the same active pharmaceutical ingredient as VAL201, the positive results from the VAL201 trial will be used to strengthen the clinical application of the VAL301 development programme and this agreement with Aptus represents an important stage in the preparation of the VAL301 compound for a clinical study.

Pre-clinical studies of the compound indicated that treatment with VAL301 should not affect bone density or fertility, two of the major problems associated with current medical treatments for endometriosis and ValiRx intends to develop VAL301 as a non-invasive, effective and better tolerated treatment for this debilitating condition.

Acquisition of IP & Joint Venture Discussions

In May 2019, ValiRx acquired the IP assets of FIT Biotech OY ("FIT Bio"). FIT Bio had been publicly listed on the First North Finland marketplace and had been developing gene delivery technologies for a number of indications and was positioning its technology as an alternative to biologics, such as vaccines, antibodies and protein-based drugs. Indeed, FIT Bio's principle technology - its Gene Transport Unit platform - had seen an initial product enter into clinical trials.

In addition to the IP assets of FIT Bio, ValiRx currently owns a potentially complementary portfolio of other genetic-based diagnostic assets. The Company is currently in discussions with a potential joint venture partner over the profitable collaboration, development and exploitation of these assets.

Financial review

At period end, ValiRx had net assets of GBP4,378,572 (2018: GBP4,647,127) of which GBP171,443 (2018: GBP590,615) comprised cash and equivalents. The Company was also pleased to announce (on 24 September 2019) its post period receipt of proceeds from a R&D Tax Credit of GBP0.423m.

The operating loss for the period narrowed substantially by 49% to GBP1,071,334 (2018: GBP2,104,689) reflecting stringent budgeting, while conducting the necessary discussions with the MHRA on VAL201 and with Aptus on VAL301 to advance both assets in clinical trials. The Company's loss before income tax similarly was substantially reduced to GBP927,342 (H1 2018: GBP2,151,788) largely as a result of a profit on the sale of fixed asset investments and no requirement to manufacture additional VAL201 drug as sufficient quantities were produced in H2 2018.

The Company continues to carefully monitor its working capital position.

Outlook

The Board is pleased with the progress of the Company in the first half of the year. We have made important strides forward across both our therapeutic and technology portfolios, with the expectation that these will deliver added value in the near term for our shareholders.

Oliver de Giorgio-Miller

Non-Executive Chairman

26 September 2019

Valirx Plc

Consolidated statement of comprehensive income

 
                                                                                                      Year ended 
                                                   Six months ended 30 
                                                           June                                      31 December 
                                  ----------------------------------------------------  ------------------------ 
                            Note                        2019                      2018                        2018 
                                                 (unaudited)               (unaudited)                   (audited) 
                                              GBP                        GBP                        GBP 
 
 Continuing operations 
 Research and development                          (206,666)                 (851,688)                 (1,698,791) 
 Administrative expenses                           (864,668)                 (920,760)                 (2,166,798) 
 Share option charge                                       -                 (332,241)                           - 
 
 
 Operating loss                                  (1,071,334)               (2,104,689)                 (3,865,589) 
 
 Fair value loss on 
  derivative 
  financial assets                                         -                  (46,892)                   (442,229) 
 Profit on the sale of 
 fixed asset 
 investments                                         153,416                         -                           - 
 Provision for bad debt                                    -                         -                   (506,755) 
 Finance costs                                       (9,424)                     (207)                    (14,565) 
                                  --------------------------  ------------------------  -------------------------- 
 
 Loss before income 
  taxation                                         (927,342)               (2,151,788)                 (4,829,138) 
 
 Income tax credit           3                       150,000                   206,000                     461,296 
                                  --------------------------  ------------------------  -------------------------- 
 
 Loss on ordinary 
  activities after 
  taxation                                         (777,342)               (1,945,788)                 (4,367,842) 
 
 Non-controlling 
  interests                                           26,773                    31,335                      69,020 
                                  --------------------------  ------------------------  -------------------------- 
 
 Loss for the period and 
  total 
  comprehensive income 
  attributable 
  to owners of the parent                          (750,569)               (1,914,453)                 (4,298,822) 
                                  ==========================  ========================  ========================== 
 
 Loss per share - basic 
  and diluted                4                       (0.11)p                   (0.51)p                     (0.94)p 
                                  ==========================  ========================  ========================== 
 

Valirx Plc

Consolidated statement of changes in shareholders' equity

 
                                                                                                                              Share                 Reverse 
                              Share                   Share                Retained                  Merger                  option             acquisition         Non-controlling 
                            capital                 premium                earnings                 reserve                 reserve                 reserve                interest                   Total 
                       GBP                     GBP                     GBP                     GBP                     GBP                     GBP                     GBP                     GBP 
 Unaudited 
 Balance at 
  1 January 
  2019                    8,680,694              19,779,905            (27,461,771)                 637,500                 885,963                 602,413                (93,764)               3,030,940 
 Loss for 
  the 
  period                          -                       -               (750,569)                       -                       -                       -                (26,773)               (777,342) 
 Issue of 
  shares                    425,762               1,012,738                       -                       -                       -                       -                       -               1,438,500 
 Costs of 
  shares 
  issued                          -               (332,285)                       -                       -                       -                       -                       -               (332,285) 
 Share 
  based 
  payment                         -                (39,268)                       -                       -                  39,268                       -                       -                       - 
 Balance at 
  30 June 
  2019                    9,106,456              20,421,090            (28,212,340)                 637,500                 925,231                 602,413               (120,537)               3,359,813 
             ======================  ======================  ======================  ======================  ======================  ======================  ======================  ====================== 
 
 Unaudited 
 Balance at 
  1 January 
  2018                    8,432,708              16,419,494            (23,378,744)                 637,500                 464,000                 602,413                (24,744)               3,152,627 
 Loss for 
  the 
  period                          -                       -             (1,914,453)                       -                       -                       -                (31,335)             (1,945,788) 
 Issue of 
  shares                    104,653               2,354,512                       -                       -                       -                       -                       -               2,459,165 
 Costs of 
  shares 
  issued                          -               (239,853)                       -                       -                       -                       -                       -               (239,853) 
 Exercise 
  of share 
  options 
  and 
  warrants                        -                 147,394                       -                       -               (147,394)                       -                       -                       - 
 Lapse of 
  share 
  options                         -                       -                   2,400                       -                 (2,400)                       -                       -                       - 
 Share 
  based 
  payment                         -                       -                       -                       -                 394,094                       -                       -                 394,094 
 Balance at 
  30 June 
  2018                    8,537,361              18,681,547            (25,290,797)                 637,500                 708,300                 602,413                (56,079)               3,820,245 
             ======================  ======================  ======================  ======================  ======================  ======================  ======================  ====================== 
 
 Audited 
 Balance at 
  1 January 
  2018                    8,432,708              16,419,494            (23,378,744)                 637,500                 464,000                 602,413                (24,744)               3,152,627 
 Loss for 
  the year                        -                       -             (4,298,822)                       -                       -                       -                (69,020)             (4,367,842) 
 Issue of 
  shares                    247,986               3,861,177                       -                       -                       -                       -                       -               4,109,163 
 Costs of 
  shares 
  issued                          -               (500,766)                       -                       -                       -                       -                       -               (500,766) 
 Lapse of 
  share 
  options                         -                       -                 215,795                       -               (215,795)                       -                                               - 
 Share 
  based 
  payment                         -                       -                       -                       -                 637,758                       -                       -                 637,758 
 Balance at 
  31 
  December 
  2018                    8,680,694              19,779,905            (27,461,771)                 637,500                 885,963                 602,413                (93,764)               3,030,940 
             ======================  ======================  ======================  ======================  ======================  ======================  ======================  ====================== 
 

Valirx Plc

Consolidated statement of financial position

 
                                                     As at 30 June                                  31 December 
                                  ---------------------------------------------------  ------------------------ 
                                                      2019                       2018                      2018 
                                               (unaudited)                (unaudited)                 (audited) 
                                             GBP                       GBP                        GBP 
 ASSETS 
 Non-current assets 
 Goodwill                                        1,602,522                  1,602,522                 1,602,522 
 Intangible assets                               1,813,405                  1,379,876                 1,623,950 
 Property, plant and equipment                           -                          -                         - 
                                  ------------------------  -------------------------  ------------------------ 
 
                                                 3,415,927                  2,982,398                 3,226,472 
                                  ------------------------  -------------------------  ------------------------ 
 
 Current assets 
 Trade and other receivables                       180,009                    746,532                   174,089 
 Tax receivable                                    611,193                    257,244                   461,193 
 Derivative financial assets                             -                     70,338                         - 
 Cash and cash equivalents                         171,443                    590,615                   372,872 
                                                                                       ------------------------ 
                                                   962,645                  1,664,729                 1,008,154 
                                  ------------------------  -------------------------  ------------------------ 
 
 Total assets                                    4,378,572                  4,647,127                 4,234,626 
                                  ========================  =========================  ======================== 
 
 SHAREHOLDERS' EQUITY 
 Share capital                                   9,106,456                  8,537,361                 8,680,694 
 Share premium account                          20,421,090                 18,681,547                19,779,905 
 Merger reserve                                    637,500                    637,500                   637,500 
 Reverse acquisition reserve                       602,413                    602,413                   602,413 
 Share option reserve                              925,231                    708,300                   885,963 
 Retained earnings                            (28,212,340)               (25,290,797)              (27,461,771) 
                                  ------------------------  -------------------------  ------------------------ 
 
                                                 3,480,350                  3,876,324                 3,124,704 
 Non-controlling interest                        (120,537)                   (56,079)                  (93,764) 
                                  ------------------------  -------------------------  ------------------------ 
 
 Total equity                                    3,359,813                  3,820,245                 3,030,940 
                                  ------------------------  -------------------------  ------------------------ 
 
 LIABILITIES 
 Current liabilities 
 Trade and other payables                          804,841                    826,882                   889,987 
 Borrowings                                        213,918                          -                   313,699 
                                  ------------------------  -------------------------  ------------------------ 
 
                                                 1,018,759                    826,882                 1,203,686 
                                  ------------------------  -------------------------  ------------------------ 
 
 Total equity and liabilities                    4,378,572                  4,647,127                 4,234,626 
                                  ========================  =========================  ======================== 
 

Valirx Plc

Consolidated cash flow statement

 
                                                                                                      Year ended 
                                                   Six months ended 30 June                          31 December 
                                       ------------------------------------------------  ----------------------- 
                                                          2019                     2018                     2018 
                                                   (unaudited)              (unaudited)                (audited) 
                                                 GBP                      GBP                      GBP 
 Cash flows from operating 
 activities 
 Operating loss                                    (1,071,334)              (2,104,689)              (3,865,589) 
 Amortisation of intangible fixed 
  assets                                                92,012                   84,800                  142,988 
 Increase in receivables                               (5,920)                 (25,005)                 (31,996) 
 Decrease in payables within one year                 (85,146)                (567,384)                (504,279) 
 Other non-cash movements                                    -                   43,991                    (957) 
 Share option charge                                         -                  332,342                  482,993 
                                       -----------------------  -----------------------  ----------------------- 
 
 Net cash outflows from operations                 (1,070,388)              (2,235,945)              (3,776,840) 
 Tax credit received                                         -                  372,850                  424,197 
 Interest paid                                         (1,205)                    (207)                    (866) 
                                       -----------------------  -----------------------  ----------------------- 
 
 Net cash outflow from operating 
  activities                                       (1,071,593)              (1,863,302)              (3,353,509) 
                                       -----------------------  -----------------------  ----------------------- 
 
 Cash flows from investing 
 activities 
 Purchase of intangible fixed assets                 (281,467)                (139,393)                (324,028) 
 Sale of non-current investments                       153,416                        -                        - 
                                       -----------------------  -----------------------  ----------------------- 
 
 Net cash outflow from investing 
  activities                                         (128,051)                (139,393)                (324,028) 
                                       -----------------------  -----------------------  ----------------------- 
 
 Cash flows from financing 
 activities 
 Share issue                                         1,226,000                2,070,000                3,720,000 
 Costs of shares issued                              (119,785)                (178,100)                (346,001) 
 Repayment of loan notes                             (108,000)                        -                 (25,000) 
                                       -----------------------  -----------------------  ----------------------- 
 
 Net cash generated from financing 
  activities                                           998,215                1,891,900                3,348,999 
                                       -----------------------  -----------------------  ----------------------- 
 
 Net decrease in cash and cash 
  equivalents                                        (201,429)                (110,795)                (328,538) 
 
 Cash and cash equivalents at start 
  of period                                            372,872                  701,410                  701,410 
                                       -----------------------  -----------------------  ----------------------- 
 
 Cash and cash equivalents at end of 
  period                                               171,443                  590,615                  372,872 
                                       =======================  =======================  ======================= 
 

Valirx Plc

Notes to the interim financial statements

   1              General information 

Valirx Plc is a company incorporated in the United Kingdom, which is listed on the Alternative Investment Market of the London Stock Exchange Plc. The address of its registered office is Stonebridge House, Chelmsford Road, Hatfield Heath, England, CM22 7BDFinancial information

The interim consolidated financial information for the six months ended 30 June 2019 has not been audited or reviewed and does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006. The Group's statutory accounts for the year ended 31 December 2018 have been delivered to the Registrar of Companies. The report of the independent auditors on those financial statements was unqualified and did not contain a statement under Sections 498 (2) or (3) of the Companies Act 2006.

The interim financial statements have been prepared in accordance with International Financial Reporting Standards ('IFRS') as adopted by the European Union, IFRIC interpretations and the Companies Act 2006 applicable to companies reporting under IFRS and under the historical cost convention. The accounting policies applied in preparing the interim financial information are consistent with those set out in the statutory accounts of the Company for the year ended 31 December 2018.

The interim consolidated financial statements are presented in pounds sterling because that is the currency of the primary economic environment in which the group operates.

   2              Taxation 
 
                                              Six months             Six months 
                                                   ended                  ended    Year ended 
                                                 30 June                30 June   31 December 
                                      ------------------  ---------------------  ------------ 
                                                    2019                   2018          2018 
                                             (unaudited)            (unaudited)     (audited) 
                                              GBP                  GBP                GBP 
 United Kingdom corporation tax 
  at 19% 
  Current period - R & D Tax 
   credit                                      (150,000)              (206,000)     (461,193) 
  Prior period - R & D Tax credits                     -                      -         (103) 
                                      ------------------  ---------------------  ------------ 
 
 Income tax credit                             (150,000)              (206,000)     (461,296) 
                                      ==================  =====================  ============ 
 
   3              Loss per ordinary share 

The loss and number of shares used in the calculation of loss per share are as follows:

 
                                               Six months       Six months 
                                                    ended            ended          Year ended 
                                                  30 June          30 June         31 December 
                                      -------------------  ---------------  ------------------ 
                                                     2019             2018                2018 
                                              (unaudited)      (unaudited)           (audited) 
 Basic: 
 Loss for the financial period                  (777,342)      (1,945,788)         (4,367,842) 
 Non-controlling interest                          26,773           31,335              69,020 
                                      -------------------  ---------------  ------------------ 
 
                                                (750,569)      (1,914,453)         (4,298,822) 
                                      ===================  ===============  ================== 
 
 Weighted average number of shares            691,640,169      384,343,833         458,715,753 
 Loss per share                                   (0.11)p          (0.51)p             (0.94)p 
                                      ===================  ===============  ================== 
 

The outstanding share options and share warrants would have no dilutive effect on the loss per share.

   4              Dividends 

The directors do not propose to declare a dividend in respect of the period.

   5              Share capital 
 
                                      30 June 2019                            30 June 2018 
                        ---------------------------------------  -------------------------------------- 
                               Number                 GBP              Number                GBP 
                                 (unaudited)        (unaudited)         (unaudited)         (unaudited) 
 Allotted, called up 
  and fully paid 
 Ordinary shares of 
  0.1p each                    1,024,057,953          1,024,059         454,962,717             454,964 
 Deferred shares of 
  5.0p each                       58,378,365          2,918,918          58,378,365           2,918,918 
 Deferred shares of 
  0.9p each                      157,945,030          1,421,505         157,945,030           1,421,505 
 Deferred shares of 
  12.4p each                      30,177,214          3,741,974          30,177,214           3,741,974 
                        ====================                     ================== 
                                                      9,106,456                               8,537,361 
                                              =================                      ================== 
 
                                               31 December 2018 
                        --------------------------------------- 
                                      Number                GBP 
 Allotted, called up 
  and fully paid                 (unaudited)        (unaudited) 
 Ordinary shares of 
  0.1p each                      598,296,049            598,297 
 Deferred shares of 
  5.0p each                       58,378,365          2,918,918 
 Deferred shares of 
  0.9p each                      157,945,030          1,421,505 
 Deferred shares of 
  12.4p each                      30,177,214          3,741,974 
                        ==================== 
                                                      8,680,694 
                                              ================= 
 

-- On 28 February 2019, the Company raised GBP0.50 million, before expenses, by way of a placing of 83,333,333 ordinary shares of 0.1p each at a price of 0.60p per share;

-- On 1 May 2019, the Company raised GBP0.426 million, before expenses, under the Subscription Agreement previously reported, by the issue of 71,000,000 at a price of 0.60p per share;

-- On 18 June 2019, the Company raised GBP0.30 million, before expenses, by way of a placing of 150,000,000 ordinary shares of 0.1p each at a price of 0.20p per share;

-- On 25 June 2019, the Company issued 121,428,571 ordinary shares of 0.1p each at a price of 0.175p per share in consideration for the termination of the Subscription Agreement at an agreed fee of GBP212,500.

   6              Copies of interim results 

Copies of the interim results can be obtained from the website www.valirx.com. From this site you may access our financial reports and presentations, recent press releases and details about the company and its operations.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IR BIGDCSXDBGCU

(END) Dow Jones Newswires

September 26, 2019 02:01 ET (06:01 GMT)

Valirx (LSE:VAL)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Valirx Charts.
Valirx (LSE:VAL)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Valirx Charts.